login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
INCYTE CORP (INCY) Stock News
USA
- NASDAQ:INCY -
US45337C1027
-
Common Stock
108.16
USD
+2.18 (+2.06%)
Last: 11/11/2025, 8:14:51 PM
109.714
USD
+1.55 (+1.44%)
Pre-Market:
11/12/2025, 8:45:13 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
INCY Latest News, Press Relases and Analysis
All
Press Releases
9 days ago - By: Chartmill
- Mentions:
HSY
IP
KMB
ARE
...
Stay informed with the top movers within the S&P500 index on Monday.
9 days ago - By: Chartmill
- Mentions:
KMB
IDXX
DXCM
ORLY
...
These S&P500 stocks have an unusual volume in today's session
an hour ago - By: Benzinga
Peering Into Incyte Corp's Recent Short Interest
6 days ago - By: Incyte
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
8 days ago - By: Zacks Investment Research
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
8 days ago - By: Prelude Therapeutics, Incorporated
- Mentions:
PRLD
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
9 days ago - By: Chartmill
- Mentions:
HSY
IP
KMB
IBKR
...
Exploring the top movers within the S&P500 index during today's session.
9 days ago - By: Incyte
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
13 days ago - By: Incyte
Incyte to Present at Upcoming Investor Conferences
15 days ago - By: Chartmill
- Mentions:
SHW
RF
EW
LH
...
These S&P500 stocks have an unusual volume in today's session
15 days ago - By: The Motley Fool
Incyte (INCY) Q3 2025 Earnings Call Transcript
15 days ago - By: Investor's Business Daily
Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views
15 days ago - By: Chartmill
Incyte Corp (NASDAQ:INCY) Reports Strong Q3 2025 Earnings, Beating Estimates
15 days ago - By: Incyte
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
16 days ago - By: Benzinga
Exploring Incyte's Earnings Expectations
16 days ago - By: Incyte and Enable Injections
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
18 days ago - By: Incyte
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
19 days ago - By: Eli Lilly and Company
- Mentions:
LLY
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
23 days ago - By: Zacks Investment Research
Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice
23 days ago - By: Zacks Investment Research
- Mentions:
GSK
NVS
QGEN
Will Positive Regulatory Updates Further Boost INCY Stock?
24 days ago - By: Incyte
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
Please enable JavaScript to continue using this application.